A new artificial intelligence company called Radical Numerics has launched with $50 million in funding, aiming to build what it describes as a general biological intelligence platform, according to SiliconANGLE.
The company's stated ambition is to apply broad AI reasoning to biology — not just narrow, single-purpose models trained for one disease or one protein, but a more generalized system capable of understanding biological processes across many domains.
The term "general biological intelligence" echoes the AI field's long-running pursuit of artificial general intelligence, but applied specifically to life sciences. The framing suggests Radical Numerics believes current AI tools in drug discovery and biology are too siloed, and that a unified platform could unlock insights that task-specific models miss.
With $50 million in initial backing, the startup enters a crowded but fast-growing field. Pharma companies and biotech investors have poured billions into AI-driven drug discovery in recent years, with firms like Recursion Pharmaceuticals, Isomorphic Labs, and others competing to reshape how medicines are found and developed.
Details about Radical Numerics' founding team, specific technology approach, or investor lineup were not available in the initial report from SiliconANGLE.
If the company can deliver on its platform vision, it could accelerate the timeline from biological hypothesis to therapeutic candidate — a process that traditionally takes years and costs hundreds of millions of dollars.